摘要
目的探讨肺腺癌中表皮生长因子受体(EGFR)基因突变及人表皮生长因子受体2(HER-2)、血管内皮生长因子(VEGF)的表达与临床病理因素间的关系。方法采用ARMS-PCR法检测10例正常肺组织及49例肺腺癌组织的EGFR基因突变的情况,同时应用免疫组织化学方法检测HER-2和VEGF蛋白表达水平。结果 (1)肺腺癌组织标本EGFR基因突变率及HER-2、VEGF蛋白表达率均比正常肺组织高(χ2=10.875 6,P=0.001;χ2=12.456 0,P=0.000;χ2=6.775 2,P=0.009)。(2)EGFR突变的发生与患者性别、是否吸烟有关(P<0.05),与年龄、肿块大小、肿瘤分化程度、有无淋巴结转移、TNM分期、有无胸膜浸润无关(P>0.05)。HER-2与VEGF蛋白表达均与肿瘤的分化程度、肿块大小、TNM分期、有无淋巴结转移、有无胸膜浸润相关(P<0.05),与患者性别、年龄、有无吸烟史无关(P>0.05)。(3)肺腺癌中HER-2与VEGF的表达呈正相关(r=0.376 4,P=0.007 7)。结论 EGFR突变与肺腺癌的发生密切相关,其在女性、非吸烟者的高表达有重要的临床意义。HER-2和VEGF在肺癌的发生、发展、转移中起协同作用,有助于临床评估预后,并为肺腺癌的新分子靶向治疗提供理论依据。
Objective To investigate the gene mutation of epithelial growth factor receptor（EGFR）and the expressions of human epiderma1 growth factor receptor 2（HER-2）and vascular endothelial growth factor（VEGF）in lung adenocarcinoma and their relationships with the clinical pathological factors.Methods ARMS-PCR method was used to detect the gene mutation of EGFR in49 lung adenocarcinoma specimens and 10 normal tissue specimens.Immunohistochemical method was also used to detect the expressions of the HER-2and VEGF in them.Results（1）The mutation rates of EGFR and the positive rates of HER-2and VEGF in lung adenocarcinoma were significantly higher than those in the normal tissues（P〈0.01）.（2）The occurs of EGFR mutation were correlated with sex and the smoking habit（P〈0.05）;but not correlated with age,the size of tumor,differential,lymph nodes metastasis,TNM stages and pleural invasion（P〉0.05）.The HER-2and VEGF protein expressions in lung adenocarcinoma were correlated with differential,the size of tumor,TNM stages,lymph nodes metastasis and pleural invasion（P〈0.05）;but not correlated with sex,age,and the smoking habit（P〉0.05）.（3）The expressions of HER-2and VEGF protein in the lung adenocarcinoma were positively correlated with each other（P〈0.01）.Conclusion EGFR mutation is closely related to the occurrence of lung adenocarcinoma,its high expressions in the women,non smoking people have important clinical significance.HER-2and VEGF could promote the lung adenocarcinoma′s occurrence,development and transfer.They could be used to evaluate the patients′prognosis,and provide new molecular targeted therapy.
出处
《国际检验医学杂志》
CAS
2016年第20期2843-2846,共4页
International Journal of Laboratory Medicine
关键词
肺腺癌
表皮生长因子受体
人表皮生长因子受体2
血管内皮生长因子
lung adenocarcinoma
epithelial growth factor receptor
epidermal growth factor receptor 2
vascular endothelial growth factor
